NCT03263767 (CYRIC) is a Phase 2 clinical trial of Fludarabine in Graft Versus Host Disease, sponsored by Nantes University Hospital.

Who is sponsoring NCT03263767?

NCT03263767 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT03263767?

Interventions in NCT03263767: Fludarabine, Clofarabine, Full body irradiation, Cyclophosphamide, Cyclophosphamide, stem cell transplantation, nuclear cells, Thymoglobulin Injectable Product.

What condition does NCT03263767 study?

NCT03263767 studies Graft Versus Host Disease.

Is NCT03263767 still recruiting?

NCT03263767 is currently terminated. Last updated 15 July 2022.

Last reviewed 2022-07-15 · How we verify

NCT03263767: CYRIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

Terminated Phase 2 Last updated 15 July 2022

What this trial tests

Phase 2 trial testing Fludarabine in Graft Versus Host Disease in 47 participants. Terminated before completion.

Timeline

15 January 2018

Primary endpoint
21 October 2021

21 June 2022

Quick facts

Lead sponsor	Nantes University Hospital
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	15 January 2018
Primary completion	21 October 2021
Estimated completion	21 June 2022
Sites	1 location across France

Drugs / interventions tested

Fludarabine (FLUDARABINE) — full drug profile →
Clofarabine (CLOFARABINE) — full drug profile →
Full body irradiation
Cyclophosphamide (cyclophosphamide) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
stem cell transplantation
nuclear cells
Thymoglobulin Injectable Product — full drug profile →

Conditions studied

Graft Versus Host Disease — all drugs for Graft Versus Host Disease →

Sponsor

Nantes University Hospital

Who can join

Adults 18 to 70, any sex, with Graft Versus Host Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute or chronic graft versus host disease is still the major complication of stem cells transplantation regarding morbidity and mortality. Recently, high dose cyclophosphamide utilization early after post-transplantation (day+ 3 and +4) not only for patients with HLA- haploidentical donor but also for patients with Human Leukocyte Antigen (HLA)-compatible donor, showed a great control of graft versus host disease after transplantation, allowing to consider stopping immunosuppressive treatment after the transplantation (Neoral=cyclosporine, cell-cept=mycophenolate mofetil). Indeed, this step has already been completed in myeloablative transplantation in adult patients. This approach could enable to avoid in the end several complications related to long term immunosuppressive drugs administration, while promoting quicker immunity recovery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.
Williams L, Cirrone F, Cole K, Abdul-Hay M, et al · · 2020 · cited 32× · PMID 32373119 · DOI 10.3389/fimmu.2020.00636
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies.
Chevallier P, Peterlin P, Garnier A, Le Bourgeois A, et al · · 2018 · cited 13× · PMID 30323896 · DOI 10.18632/oncotarget.26083
Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.
Bourgeois AL, Jullien M, Garnier A, Peterlin P, et al · · 2023 · cited 2× · PMID 37140099 · DOI 10.1002/ctm2.1242

Verify or expand the search:

Other trials of Fludarabine

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
NCT07428486 — A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractor · Phase 1 · not yet recruiting
NCT07411599 — Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Graft Versus Host Disease

Currently open trials in the same condition.

NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07006506 — A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant · Phase 2 · recruiting
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
NCT06705062 — Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment · Phase 3 · recruiting
NCT06252870 — Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-trans · Phase 2 · recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03263767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 15 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03263767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing